Increased expression of MIP-3α has been reported in multiple myeloma17 and hepatocellular carcinoma.18 Our earlier studies have indicated that the detection of serum MIP-3α and cystatin A might contribute to improve the NPC staging and prediction of short-term clinical outcomes.19 In this study, by analyzing the relationship between MIP-3α and clinical characteristic prognostic factors, we found that patients with higher T-stage tumors were more likely to have increased levels of MIP-3α. The gene discussed is CCL20; the disease is hepatocellular carcinoma.